Characteristics, implementation of evidence-based management and outcome in patients with chronic heart failure. Results from the Norwegian heart failure registry.

European Journal of Cardiovascular Nursing

Volumn 10, Issue 1, 2011, Pages 44-49

  Grundtvig, Morten ^a   Gullestad, Lars ^b   Hole, Torstein ^c   Flønæs, Berit ^d   Westheim, Arne ^e  

^a INNLANDET HOSPITAL TRUST   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^d VESTRE VIKEN HOSPITAL TRUST   (Norway)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Disease management; Drug therapy; Female; Heart failure; Mortality; Outpatients

Indexed keywords

ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOOP DIURETIC AGENT; POTASSIUM; SODIUM; SPIRONOLACTONE; URIC ACID; WARFARIN;

AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COMORBIDITY; CONGENITAL HEART DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE REGISTRY; EVIDENCE BASED MEDICINE; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE EJECTION FRACTION; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; HYPERTROPHIC CARDIOMYOPATHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NORWAY; OUTCOME ASSESSMENT; OUTPATIENT CARE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; SODIUM BLOOD LEVEL; URIC ACID BLOOD LEVEL; VALVULAR HEART DISEASE;

AGED; AGED, 80 AND OVER; AMBULATORY CARE FACILITIES; CHRONIC DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; HEART FAILURE; HUMANS; LENGTH OF STAY; MALE; MIDDLE AGED; NORWAY; OUTCOME ASSESSMENT (HEALTH CARE); REGISTRIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79851511996     PISSN: 14745151     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcnurse.2010.04.001     Document Type: Article

References (16)

1. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart 2007, 93(9):1137-1146.
2. Krumholz H.M., Chen Y.T., Wang Y., Vaccarino V., Radford M.J., Horwitz R.I. Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J 2000, 139(1 Pt 1):72-77.
3. Krum H. The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005). Eur Heart J 2005, 26(22):2472-2474.
4. Komajda M., Follath F., Swedberg K., Cleland J., Aguilar J.C., Cohen-Solal A., et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 2003, 24(5):464-474.
5. McAlister F.A., Stewart S., Ferrua S., McMurray J.J. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004, 44(4):810-819.
6. Roccaforte R., Demers C., Baldassarre F., Teo K.K., Yusuf S. Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. Eur J Heart Fail 2005, 7(7):1133-1144.
7. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470.
8. de Groote P., Isnard R., Assyag P., Clerson P., Ducardonnet A., Galinier M., et al. Is the gap between guidelines and clinical practice in heart failure treatment being filled? Insights from the IMPACT RECO survey. Eur J Heart Fail 2007, 9(12):1205-1211.
9. Komajda M., Lapuerta P., Hermans N., Gonzalez-Juanatey J.R., van Veldhuisen D.J., Erdman E., et al. Adherence to guidelines is a predictor of outcome in chronic heart failure: the MAHLER survey. Eur Heart J 2005, 26(16):1653-1659.
10. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353(9169):2001-2007.
11. Ahmed A., Young J.B., Love T.E., Levesque R., Pitt B. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol 2007.
12. Hasselblad V., Gattis S.W., Shah M.R., Lokhnygina Y., O'Connor C.M., Califf R.M., et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007, 9(10):1064-1069.
13. Cooper H.A., Dries D.L., Davis C.E., Shen Y.L., Domanski M.J. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999, 100(12):1311-1315.
14. Andersen M.K., Markenvard J.D., Schjott H., Nielsen H.L., Gustafsson F. Effects of a nurse-based heart failure clinic on drug utilization and admissions in a community hospital setting. Scand Cardiovasc J 2005, 39(4):199-205.
15. Giordano A., Scalvini S., Zanelli E., Corrà U., Longobardi G.L., Ricci V.A., et al. Multicenter randomised trial on home-based telemanagement to prevent hospital readmission of patients with chronic heart failure. Int J Cardiol 2009, 131(2):192-199.
16. Goldstein S., Fagerberg B., Hjalmarson A., Kjekshus J., Waagstein F., Wedel H., et al. Metoprolol controlled release/extended release in patients with severe heart failure: analysis of the experience in the MERIT-HF study. J Am Coll Cardiol 2001, 38(4):932-938.